Welcome to our dedicated page for Solventum news (Ticker: SOLV), a resource for investors and traders seeking the latest updates and insights on Solventum stock.
Solventum Corporation (NYSE: SOLV) generates a steady flow of news that reflects its role in the medical instruments and supplies sector and its focus on MedSurg, Dental Solutions and Health Information Systems. News about Solventum often highlights developments in advanced wound care, portfolio changes, capital allocation decisions and strategic initiatives intended to support long-term growth.
Recent announcements include agreements and completion of the acquisition of Acera Surgical, a bioscience company focused on fully engineered materials for regenerative wound care. These updates describe how Solventum is expanding its MedSurg portfolio into the synthetic tissue matrices technology space within acute care settings. Other news covers clinical and scientific developments, such as international consensus recommendations on the use of closed incision negative pressure therapy with reticulated open cell foam dressings, which relate directly to Solventum Prevena Therapy and its application across surgical specialties.
Investors and healthcare professionals following SOLV news will also see coverage of financial results, including quarterly earnings releases and guidance updates, as well as information about Solventum’s “Transform for the Future” initiative to reshape its cost structure and support innovation. Capital markets and balance sheet actions, such as cash tender offers for outstanding notes, the sale of the purification and filtration business to Thermo Fisher Scientific Inc., and the authorization of a share repurchase program, are reported through both press releases and SEC filings.
Additional news items may feature recognition of operational capabilities, such as the Diamond Level Resiliency Badge from the Healthcare Industry Resilience Collaborative for supply chain strength in the MedSurg segment, and participation in healthcare investor conferences. By reviewing the SOLV news feed on a regular basis, readers can track how Solventum’s strategic decisions, clinical evidence, portfolio moves and financial performance are communicated to the market over time.
Solventum (NYSE: SOLV) reported second quarter 2026 net sales of $2.2 billion, up 2.2% reported and 9.5% organically. GAAP diluted EPS was $0.53, while adjusted diluted EPS was $2.55, up 50.9% year over year. Operating cash flow was $227 million and free cash flow $144 million, both above company expectations.
Organic growth was broad-based across segments, and adjusted operating margin rose to 28.4%, up 650 bps, helped by an IEEPA tariff refund and ERP-related timing benefits. Solventum announced its intent to separate the Health Information Systems segment to sharpen its focus as a MedTech company.
For full-year 2026, the company raised guidance: organic sales growth to 2.5%–3.0% (3.5%–4.0% excluding ~100 bps SKU exits), adjusted EPS to $7.10–$7.20, and free cash flow to $200–$300 million, all based on non-GAAP measures.
Solventum (NYSE: SOLV) announced its intention to separate its Health Information Systems (HIS) business as part of an ongoing portfolio optimization and three-phase transformation strategy. Solventum is evaluating multiple separation structures, including creating an independent company, combining HIS with a scaled player, or pursuing another transaction type, with the goal of maximizing shareholder value.
HIS is a healthcare software business generating $1.4 billion in annual sales, serving more than 75% of U.S. hospitals, processing about 660 million clinical documents monthly, and operating in an estimated $10 billion addressable market growing 5–6% annually. According to Solventum, a separation would allow Solventum to focus on its MedSurg and Dental Solutions businesses, while giving HIS dedicated management, strategic focus, and capital allocation flexibility. The company is targeting transaction completion within 12–18 months, but no final decision on structure or timing has been made and there is no assurance a separation will occur.
Solventum (NYSE: SOLV) will release its second quarter fiscal 2026 financial results on Wednesday, August 5, 2026, after U.S. markets close. Management will then host an earnings webcast to review the quarter and may discuss other forward-looking and material information.
The webcast is scheduled for 3:30 p.m. CDT / 4:30 p.m. EDT and can be accessed via https://investors.solventum.com. According to Solventum, investors can join by phone using U.S. dial-in +1 (800) 715-9871, international dial-in +1 (646) 307-1963, and conference ID 6342275. A replay, the earnings release, slides, and supplemental financial disclosures will be available afterward on the Investor Relations website.
Solventum (NYSE: SOLV) announced that its management will participate in a fireside chat at the Jefferies Healthcare Conference in New York on Wednesday, June 3, 2026, at approximately 9:55 a.m. EDT. A live and archived webcast will be available at investors.solventum.com.
Solventum (NYSE: SOLV) will participate in the BofA Securities Health Care Conference on Wednesday, May 13, 2026, with a management fireside chat beginning at approximately 10:00 a.m. PDT in Las Vegas. A live and archived replay will be available on the company's investor website.
Solventum (NYSE: SOLV) reported Q1 2026 results for the quarter ended March 31, 2026. Net sales $2.007B (reported -3.0%; organic +2.1%). GAAP diluted EPS $0.07; adjusted diluted EPS $1.48 (up 10.6%). Operating cash flow was $(189)M; free cash flow $(273)M.
Company affirmed full-year 2026 guidance: organic sales +2.0%–+3.0%, adjusted EPS toward high end of $6.40–$6.60, and free cash flow ~ $200M.
Solventum (NYSE: SOLV) will report its first quarter fiscal 2026 results on Tuesday, May 5, 2026 after U.S. markets close. Management will host a webcast to discuss results and other forward-looking material.
Webcast: May 5, 2026 at 3:30 p.m. CDT / 4:30 p.m. EDT; live at https://investors.solventum.com. Dial-ins: U.S. +1 (800) 715-9871, International +1 (646) 307-1963; Conference ID 6342275. Replay, press release, slides and supplemental disclosures will be available on the Investor Relations website.
Solventum (NYSE: SOLV) announced management will take part in a virtual fireside chat at the KeyBanc Healthcare Forum on Wednesday, Mar. 18, 2026 at approximately 10:30 a.m. EDT.
Investors can access a live webcast and replay via the company investor website.
Solventum (NYSE: SOLV) reported Q4 2025 results and issued full-year 2026 guidance. Q4 net sales were $1.998B, down 3.7% reported but +3.5% organic. GAAP diluted EPS was $0.36; adjusted diluted EPS was $1.57. Operating cash flow was $96M; free cash flow $33M. For 2026 the company guides organic sales +2.0%–3.0% (+3.0%–4.0% ex ~100bps SKU exit), adjusted EPS $6.40–$6.60, and free cash flow ~$200M.
Segment strength included MedSurg, Infection Prevention and Dental Solutions; Purification and Filtration was divested in Sept 2025, driving reported comparisons and debt paydown benefits.
Solventum (NYSE: SOLV) will report fourth quarter and full year fiscal 2025 results on Thursday, Feb. 26, 2026 after U.S. market close. Management will host a webcast at 3:30 p.m. CST / 4:30 p.m. EST to discuss results and fiscal 2026 outlook.
A replay, press release, presentation slides and supplemental financial disclosures will be posted on the company Investor Relations website.